secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001193125-24-123689
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA pays $22M upfront for royalty interests in three women's health assets from Daré Bioscience
--------------------------------------------------------------------------------

- XOMA paid $22M cash to Daré for royalties on XACIATO, Ovaprene, and Sildenafil Cream.
- XOMA receives low-to-high single-digit royalties on XACIATO net sales; Organon began marketing in Q4 2023.
- Synthetic royalties: low single-digit on Ovaprene (Phase 3) and Sildenafil Cream (Phase 3-ready), decreasing after return threshold.
- XOMA also acquires a portion of a milestone payment from Bayer related to Ovaprene.
- XOMA will make upside-sharing milestone payments to Daré upon achieving a pre-specified return threshold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524123689/0001193125-24-123689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524123689/d798315d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-123689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer